Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Northwestern Medicine

Sites in Chicago, IL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1125
Shown on this page
12
Current sort
Recently updated
Campus scope
Northwestern Medicine, Chicago, IL
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Northwestern Medicine, Chicago, IL. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 1057–1068 of 1,125 matching trials with a site at Northwestern Medicine, Chicago, IL.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Not applicable Interventional

GAE Using Embosphere Microspheres vs Corticosteroid Injections for Treatment of Symptomatic Knee OA (MOTION)

NCT05818150
Site status not listed — check the official record
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Embosphere Microspheres, Corticosteroid injection
Device · Drug
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
21 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
19
States / cities
Long Beach, California • Washington D.C., District of Columbia • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Nov 7, 2026, 8:45 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

NCT06100276
Site status not listed — check the official record
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AMT-162
Drug
Lead sponsor
UniQure Biopharma B.V.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
11
States / cities
Phoenix, Arizona • Irvine, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Nov 7, 2026, 8:45 PM EST
Active, not recruiting Phase 1 Interventional

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

NCT04185883
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Interventions
Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
55
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Nov 7, 2026, 8:45 PM EST
Active, not recruiting Phase 1 Interventional

Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia

NCT03513484
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A, Fibroblast Growth Factor Basic Form Measurement, FLT3 Internal Tandem Duplication, Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Azacitidine, Laboratory Biomarker Analysis, Nintedanib
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Nov 7, 2026, 8:45 PM EST
Recruiting No phase listed Observational

Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs

NCT04613921
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Liver Diseases, Liver Cirrhosis, Acute-On-Chronic Liver Failure, Liver Transplant; Complications
Interventions
Observational Protocol
Other
Lead sponsor
European Foundation for Study of Chronic Liver Failure
Other
Eligibility
18 Years to 80 Years
Enrollment
3,000 participants
Timeline
2021 – 2026
U.S. locations
18
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Nov 7, 2026, 8:45 PM EST
Recruiting No phase listed Observational

Collecting Tissue Samples for Future Research From Women Undergoing Surgery for Breast Cancer

NCT00898131
Status at this site: Recruiting
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
Female only
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Nov 7, 2026, 8:45 PM EST
Active, not recruiting Not applicable Interventional

Study of Procedural Efficiency in EBUS With Dual Versus Single NEEDLEs: Evaluating the Value of a Second Needle in EBUS as it Pertains to Economic and Environmental Impact

NCT07218042
Site status not listed — check the official record
View directory record Official record
Conditions
Mediastinal and Hilar Lymphadenopathy
Interventions
We randomized patients to the two arms above; there was no specific intervention performed other than randomizing patients to one or two needles.
Diagnostic Test
Lead sponsor
Christopher Kapp
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Sacramento, California • Chicago, Illinois • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Nov 7, 2026, 8:45 PM EST
Active, not recruiting Phase 3 Interventional

Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

NCT04988386
Site status not listed — check the official record
View directory record Official record
Conditions
Amyloid Cardiomyopathy, Transthyretin-Related
Interventions
Acoramidis (AG10)
Drug
Lead sponsor
Eidos Therapeutics, a BridgeBio company
Industry
Eligibility
18 Years to 90 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
26
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Nov 7, 2026, 8:45 PM EST
Active, not recruiting Phase 2 Interventional

Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast

NCT04009044
Site status not listed — check the official record
View directory record Official record
Conditions
Cancer Survivor, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma
Interventions
Afimoxifene, Core Biopsy, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Nov 7, 2026, 8:45 PM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Consent for Use of Stored Patient Specimens for Future Testing

NCT00031408
Site status not listed — check the official record
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
Not listed
Enrollment
17,444 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2027
U.S. locations
62
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Nov 7, 2026, 8:45 PM EST
Active, not recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

NCT06257875
Site status not listed — check the official record
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Lutikizumab, Adalimumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
48
States / cities
Chula Vista, California • Coronado, California • Huntington Beach, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Nov 7, 2026, 8:45 PM EST
Active, not recruiting Not applicable Interventional

P-15L Bone Graft in Transforaminal Lumbar Interbody Fusion With Instrumentation

NCT03438747
Site status not listed — check the official record
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
P-15L Bone Graft, Local autologous bone in a TLIF with Instrumentation
Device · Other
Lead sponsor
CeraPedics, Inc
Industry
Eligibility
22 Years to 80 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
34
States / cities
Birmingham, Alabama • Glendale, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Nov 7, 2026, 8:45 PM EST

About this Northwestern Medicine institution page

What this page lists
ClinicalTrials.gov records that list Northwestern Medicine in Chicago, IL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Northwestern University at any site, browse by condition, or browse by U.S. city.